MOUNTAIN VIEW, Calif. (September 19, 2006) – Conceptus, Inc. (Nasdaq: CPTS), developer of the non-incisional permanent birth control procedure Essure®, today announced that Mark Sieczkarek, Conceptus’ chief executive officer, will present at the UBS 2006 Global Life Sciences Conference on Tuesday, September 26, 2006, at 12:30 PM Eastern Time. The conference will be held at the Grand Hyatt Hotel in New York City from September 25 through September 28, 2006.

Individuals may listen to a live web cast of the presentation by logging on to the Investor Relations section of Conceptus’ web site www.conceptus.com a few minutes prior to start time to download any necessary software.

The UBS Global Life Sciences Conference will feature representatives from over 350 companies from the following major life sciences sectors: biotechnology, life sciences (genomics and tools), medical technology, pharmaceuticals and specialty pharmaceuticals.

About the Essure Procedure
The Essure procedure deploys a soft micro-insert into the fallopian tube through the cervix using a minimally invasive transcervical tubal access catheter. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the fallopian tube. An Essure procedure does not require cutting or penetrating the abdomen and can be performed in a less costly procedure setting without general anesthesia. A woman is able to return home about 45 minutes after the procedure is completed. There is a three-month waiting period after the procedure during which women must use another form of birth control. The Essure procedure is 99.80% effective after four years of follow-up. The Essure procedure has been demonstrated in a small portion of the women undergoing clinical studies to be 99.74% effective based on 5 years of follow-up. Five year follow-up of all patients in clinical trials is ongoing.

About Conceptus
Conceptus, Inc. manufactures and markets the Essure Permanent Birth Control system, an innovative medical device and procedure designed to provide a non-incisional alternative to tubal ligation, which is currently the leading form of birth control worldwide. The availability of the Essure procedure in the U.S. is expected to open up a market currently occupied by incisional tubal ligation and vasectomy, which combined account for over 1 million procedures annually.

Additional information about the Essure procedure is available at www.essure.com or by calling the Essure Information Center at 1-877-ESSURE1. Additional information about Conceptus is available at www.conceptus.com or by calling 1-877-ESSURE2.